These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 24291104)
1. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant. Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104 [TBL] [Abstract][Full Text] [Related]
2. Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant. Shimizu Y; Ishii T; Ogawa K; Sasaki S; Matsui H; Nakayama M Eur J Pharmacol; 2015 Oct; 764():220-227. PubMed ID: 26048307 [TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452 [TBL] [Abstract][Full Text] [Related]
4. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295 [TBL] [Abstract][Full Text] [Related]
5. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers. Li QR; Zhao H; Zhang XS; Lang H; Yu K Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201 [TBL] [Abstract][Full Text] [Related]
6. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity. Sinha N; Chowdhury S; Sarkar RR Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795 [TBL] [Abstract][Full Text] [Related]
7. Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened. Tao H; Jin Q; Koo DI; Liao X; Englund NP; Wang Y; Ramamurthy A; Schultz PG; Dorsch M; Kelleher J; Wu X Chem Biol; 2011 Apr; 18(4):432-7. PubMed ID: 21513879 [TBL] [Abstract][Full Text] [Related]
8. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Proctor AE; Thompson LA; O'Bryant CL Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609 [TBL] [Abstract][Full Text] [Related]
10. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. De Smaele E; Ferretti E; Gulino A Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266 [TBL] [Abstract][Full Text] [Related]
11. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788 [TBL] [Abstract][Full Text] [Related]
12. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392 [TBL] [Abstract][Full Text] [Related]
13. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Larsen AR; Bai RY; Chung JH; Borodovsky A; Rudin CM; Riggins GJ; Bunz F Mol Cancer Ther; 2015 Jan; 14(1):3-13. PubMed ID: 25376612 [TBL] [Abstract][Full Text] [Related]
14. B13, a well-tolerated inhibitor of hedgehog pathway, exhibited potent anti-tumor effects against colorectal carcinoma in vitro and in vivo. Wu H; Zhang L; Chen B; Ou B; Xu J; Tian N; Yang D; Ai Y; Chen Q; Quan D; Zhang T; Lv L; Tian Y; Zhang J; Wu S Bioorg Chem; 2023 Jun; 135():106488. PubMed ID: 36989734 [TBL] [Abstract][Full Text] [Related]
15. Vismodegib. Meiss F; Zeiser R Recent Results Cancer Res; 2014; 201():405-17. PubMed ID: 24756807 [TBL] [Abstract][Full Text] [Related]
16. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor. Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740 [TBL] [Abstract][Full Text] [Related]
17. Structural optimization on a virtual screening hit of smoothened receptor. Song S; Jiang J; Zhao L; Wang Q; Lu W; Zheng C; Zhang J; Ma H; Tian S; Zheng J; Luo L; Li Y; Yang ZJ; Zhang X Eur J Med Chem; 2019 Jun; 172():1-15. PubMed ID: 30939349 [TBL] [Abstract][Full Text] [Related]
18. Hedgehog Pathway Inhibition. Sekulic A; Von Hoff D Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418 [TBL] [Abstract][Full Text] [Related]
19. Discovery and preclinical development of vismodegib. Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041 [TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity. Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]